NasdaqGM:WVEPharmaceuticals
Wave Life Sciences (WVE) Is Down 5.2% After Wider Q2 Losses And RNA Editing Updates - What's Changed
In late July 2026, Wave Life Sciences reported Q2 2026 results showing sales of US$2.27 million versus US$8.70 million a year earlier, with net loss widening to US$69.36 million and basic loss per share from continuing operations at US$0.34.
Despite weaker quarterly revenue, the company highlighted progress in its RNAi and RNA editing programs, including positive data for obesity candidate WVE-007 and preparations for an FDA meeting on a potential accelerated approval pathway for AATD...